{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:53:26Z","timestamp":1792155206154,"version":"4.4.0"},"reference-count":38,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alzheimer's &amp;amp; Dementia"],"published-print":{"date-parts":[[2015,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Amyloid positron emission tomography (PET) has become an important tool to identify amyloid\u2010\u03b2 (A\u03b2) pathology in Alzheimer's disease (AD) patients. Here, we determined the diagnostic value of the amyloid PET tracer [\n                      <jats:sup>18<\/jats:sup>\n                      F]flutemetamol in relation to A\u03b2 pathology at autopsy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]flutemetamol PET was carried out in a cohort of 68 patients included in a [\n                      <jats:sup>18<\/jats:sup>\n                      F]flutemetamol amyloid PET imaging end\u2010of\u2010life study (GE067\u2010007). At autopsy, AD pathology was determined and A\u03b2 plaque pathology was classified into phases of its regional distribution (0\u20135).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]flutemetamol PET was universally positive in cases with advanced stage postmortem A\u03b2 pathology (A\u03b2 phases 4 and 5). Negative amyloid PET was universally observed in nondemented or non\u2010AD dementia cases with initial A\u03b2 phases 1 and 2, whereas 33.3% of the phase 3 cases were positive.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      [\n                      <jats:sup>18<\/jats:sup>\n                      F]flutemetamol amyloid PET detects primarily advanced stages of A\u03b2 pathology in preclinical and symptomatic AD cases.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1016\/j.jalz.2015.05.018","type":"journal-article","created":{"date-parts":[[2015,7,3]],"date-time":"2015-07-03T08:24:36Z","timestamp":1435911876000},"page":"975-985","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":158,"title":["[\n                    <sup>18<\/sup>\n                    F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid\u2010\u03b2 pathology"],"prefix":"10.1002","volume":"11","author":[{"given":"Dietmar Rudolf","family":"Thal","sequence":"first","affiliation":[{"name":"Institute of Pathology\u2014Laboratory of Neuropathology, Center for biomedical Research University of Ulm  Ulm Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas G.","family":"Beach","sequence":"additional","affiliation":[{"name":"Civin Laboratory for Neuropathology Banner Sun Health Research Institute  Sun City AZ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Zanette","sequence":"additional","affiliation":[{"name":"Life Sciences R&amp;D Biometrics GE Healthcare  Princeton NJ USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kerstin","family":"Heurling","sequence":"additional","affiliation":[{"name":"Life Sciences R&amp;D GE Healthcare  Uppsala Sweden"},{"name":"Department of Surgical Sciences: Radiology Uppsala University  Uppsala Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aruna","family":"Chakrabarty","sequence":"additional","affiliation":[{"name":"Pathology and Tumour Biology, Leeds Institute of Molecular Medicine St. James Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azzam","family":"Ismail","sequence":"additional","affiliation":[{"name":"Pathology and Tumour Biology, Leeds Institute of Molecular Medicine St. James Hospital  Leeds UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian P.L.","family":"Smith","sequence":"additional","affiliation":[{"name":"Life Sciences R&amp;D GE Healthcare  Amersham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Buckley","sequence":"additional","affiliation":[{"name":"Life Sciences R&amp;D GE Healthcare  Amersham UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2015,7]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-291X(84)80190-4"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.82.12.4245"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20009"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-012-1051-z"},{"key":"e_1_2_7_6_1","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2174\/1568026611313080004","article-title":"Fluorine\u201018 radiolabeled heterocycles as PET tracers for imaging beta\u2010amyloid plaques in Alzheimer's disease","volume":"13","author":"Zeng F","year":"2013","journal-title":"Curr Top Med Chem"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/WAD.0b013e31821300bc"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2990-05.2005"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awn016"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70142-4"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2014.4144"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.58.12.1791"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.10.007"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.005"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2011.03.003"},{"issue":"2","key":"e_1_2_7_16_1","doi-asserted-by":"crossref","first-page":"S137","DOI":"10.1007\/s00406-013-0449-5","article-title":"Pathology of clinical and preclinical Alzheimer's disease","volume":"263","author":"Thal DR","year":"2013","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt362"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/ana.22068"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-009-0485-4"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-014-1349-0"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1582-4934.2008.00411.x"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awt286"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(12)70227-2"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2013.02.006"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropsychologia.2008.02.008"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awu367"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-1281(11)80100-5"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.jnen.0000229986.17548.27"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-014-2753-3"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-008-0358-2"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-012-2178-9"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-012-0583-x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneurol.2011.153"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurobiolaging.2009.02.011"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-013-1185-7"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00308809"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.4.479"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-009-0612-2"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1440-1789.2003.00522.x"}],"container-title":["Alzheimer's &amp; Dementia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526015002162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1552526015002162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.jalz.2015.05.018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2015.05.018","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1016\/j.jalz.2015.05.018","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1016\/j.jalz.2015.05.018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,7]],"date-time":"2025-10-07T20:19:48Z","timestamp":1759868388000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1016\/j.jalz.2015.05.018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["10.1016\/j.jalz.2015.05.018"],"URL":"https:\/\/doi.org\/10.1016\/j.jalz.2015.05.018","archive":["Portico"],"relation":{},"ISSN":["1552-5260","1552-5279"],"issn-type":[{"value":"1552-5260","type":"print"},{"value":"1552-5279","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"2015-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}